XBiotech
XBIT | NASDAQ
$1.85
-$0.10 (-5.37%)
At close: Nov 16, 2026, 4:00 PM ET
$1.81
-$0.04 (-2.16%)
After-hours:
Nov 16, 2026, 7:21 PM ET
XBiotech Company Profile
Company profile explainedCompany Profile
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
Key Executives
| Name | Position |
|---|---|
| Sushma Shivaswamy | Interim CEO & Chief Scientific Officer |
| Angela Hu | Director of Finance |
| John Simard | Founder & Chairman |
| Qian Wu | Senior Vice President of Clinical Operations & Analytical Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 4 | Filing |
| Oct 28, 2026 | 3 | Filing |
| Oct 28, 2026 | 4 | Filing |
| Oct 26, 2026 | 8-K | Current Report |
| Oct 02, 2026 | ARS | Filing |
| Oct 02, 2026 | DEF 14A | Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| May 14, 2026 | 10-Q | Quarterly Report |
| Apr 29, 2026 | 10-K/A | [Amend] Annual Report |
| Mar 13, 2026 | 10-K | Annual Report |
XBiotech
| Country | United States |
| IPO Date | Apr 15, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 87 |
| CEO | Sushma Shivaswamy |
Contact Details
5217 Winnebago Lane Austin,
Texas 78744 United States
Stock Details
| Ticker Symbol | XBIT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001626878 |
| CUSIP Number | 98400H102 |
| ISIN Number | CA98400H1029 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove XBIT